P190 Nanostructured formulation of a novel hybrid iminosugar/steroid agent for application in cystic fibrosis lung disease

Chronic bacterial infections and exaggerated inflammation of airways are hallmarks of Cystic Fibrosis (CF) and are significant causes of morbidity and mortality in CF patients. Accordingly, development of novel anti-inflammatory and anti-bacterial agents, to combine with CFTR modulators, is a key goal in CF drug discovery. Recent studies, granted by Italian Cystic Fibrosis Research Foundation, revealed the ability of two compounds, the iminosugar L-Miglustat and beta-sitosterol (BSS), to reduce both the levels of inflammation and the bacterial load in murine models of CF infection.